Hypoglycemia-induced c-Jun Phosphorylation Is Mediated by c-Jun N-terminal Kinase 1 and Lyn Kinase in Drug-resistant Human Breast Carcinoma MCF-7/ADR Cells*

(Received for publication, November 7, 1996)

Xin Liu , Anjali K. Gupta , Peter M. Corry and Yong, J. Lee Dagger

From the Department of Radiation Oncology, Research Laboratories, William Beaumont Hospital, Royal Oak, Michigan 48073

ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
FOOTNOTES
REFERENCES


ABSTRACT

We studied the signal transduction mechanism that is involved in c-Jun phosphorylation evident after glucose deprivation in MCF-7/ADR cells. Glucose deprivation caused an immediate increase in tyrosine phosphorylation in MCF-7/ADR cells and specifically activated Lyn kinase, a src family tyrosine kinase. In addition, hypoglycemic treatment strongly activated c-Jun N-terminal kinase 1 (JNK1), leading to the phosphorylation and activation of c-Jun. Experiments with Lyn antisense oligonucleotides demonstrated that Lyn kinase activation was responsible for the activation of JNK1 but not extracellular signal-regulated kinase. We also observed glucose deprivation-induced Ras activation in MCF-7/ADR cells. These results indicate a possible Ras-dependent signaling pathway involving Lyn kinase and JNK1, which leads to the glucose deprivation-induced responses in MCF-7/ADR cells.


INTRODUCTION

The initiation of angiogenic activity is recognized as one of the critical steps in tumor development and metastasis. It has been demonstrated that ischemia/hypoxia (1, 2), radiation (3, 4), or tumor promoters (5) can stimulate the synthesis of angiogenic factor(s), such as basic fibroblast growth factor (bFGF)1 and vascular endothelial growth factor. Angiogenic factors can trigger the formation of new blood vessels, allowing more nutrients and O2 to reach cancer cells, and also provide a route for metastasis. A fundamental question that remains unanswered is how the stresses stimulate the synthesis of these angiogenic factors.

The genes encoding angiogenic factors such as bFGF have been shown to contain AP-1 cis-acting elements (12-O-tetradecanoylphorbol-13-acetate response element) in their promoter region (6,-8), which are recognized by AP-1 transcription factors (Jun and Fos family proteins) (9, 10). The activity of AP-1 transcription factors is controlled by transcriptional and post-transcriptional regulation. It has been shown that transcriptional activation of the c-jun gene is exerted through the distal and proximal AP-1 binding sites (9), which are recognized by either c-Jun homodimers or c-Jun/activating transcription factor-2 heterodimers (9, 10). The transcriptional activity of these binding factors is stimulated by the phosphorylation of c-Jun (11-13), and possibly activating transcription factor-2 (14, 15), by c-Jun N-terminal kinase (JNK). The induction of c-fos transcription is mediated by the serum response element (SRE) and the v-sis conditioned medium induction element. The SRE is recognized by a homodimer of serum response factor (16), and the binary SRE-serum response factor complex interacts with the ternary complex factor (TCF) (17). It has been demonstrated that the activity of TCF is rapidly increased in response to stimulation with various agents, such as growth factors, which leads to the activation of extracellular signal-regulated kinase (ERK). ERK has been shown to be responsible for the phosphorylation and activation of TCF (18, 19). Taken together, phosphorylation of c-Jun and other transcription factors appears to be the link between the transcriptional activity of AP-1 containing genes and ERK or JNK kinase signaling cascades, allowing the expression of these genes to be triggered by different stimuli.

We have previously demonstrated that hypoglycemia activates the expression of c-jun and c-fos genes, which results in an increase in AP-1 activity and subsequent bFGF gene expression in drug-resistant human breast carcinoma MCF-7/ADR cells (20). In an effort to fully understand the signaling mechanism that triggered these responses, we studied the phosphorylation events that may lead to the activation of AP-1 transcription factors. The study reported here demonstrates that hypoglycemic treatment of MCF-7/ADR cells activated Lyn kinase, which increased the activity of JNK1 and the phosphorylation of c-Jun. These results suggest a possible signal transduction pathway in MCF-7/ADR cells that responds to hypoglycemic conditions.


MATERIALS AND METHODS

Construction of JNK1 Expression Vector

The expression vector pCMV5-JNK1 (21) was kindly provided by Dr. M. Karin (University of California, San Diego, La Jolla, CA). This vector encodes the human JNK1 with a N-terminal FLAG tag. To obtain stably transfected cells, we subcloned the HindIII-XbaI fragment of pCMV5-JNK1 containing the entire JNK1 coding region into the expression vector pcDNA3. The resulting plasmid was named pcDNA3-JNK1FLAG.

Cell Culture and Transfections

Drug-resistant human breast carcinoma (MCF-7/ADR) cells were cultured in McCoy's 5A medium with 10% bovine calf serum (Hyclone, Logan, UT) and 26 mM sodium bicarbonate. Two or three days prior to the experiments, cells were plated into T-75 flasks or 60- or 100-mm Petri dishes. The flasks/Petri dishes containing cells were kept in a 37 °C humidified incubator with a mixture of 95% air and 5% CO2.

Transfections were performed using Lipofectace reagent (Life Technologies, Inc.) per the manufacturer's instructions. McCoy's 5A medium containing 400 µg/ml Geneticin (Life Technologies, Inc.) was placed onto cells 48 h post-transfection to select for transfected cells.

Glucose Deprivation Treatment

MCF-7/ADR cells were rinsed three times with Hanks' balanced salt solution prewarmed at 37 °C. Cells were then treated with glucose-free McCoy's 5A medium with 10% dialyzed bovine calf serum (Life Technologies, Inc.) for the specified time intervals.

Assay for c-Jun-associated Kinase Activity

To assay for c-Jun-associated kinase activity, cells were lysed in lysis buffer (100 mM sodium phosphate, pH 7.4, 150 mM NaCl, 1% Nonidet P-40, and 0.1% SDS). The lysates were precleared with glutathione-agarose beads followed by incubation with 10 µl of GST-c-Jun (1-169) agarose beads (Upstate Biotechnology, Lake Placid, NY) at 4 °C for 1 h. The beads were collected by centrifugation at 10,000 × g for 2 min and washed twice with the lysis buffer and twice with the kinase assay buffer (20 mM Hepes, pH 7.5, 150 mM NaCl, 10 mM MgCl2, 0.1% Triton X-100, 10% glycerol). The beads were then resuspended in 30 µl of kinase assay buffer containing 20 µM [gamma -32P]ATP (2000 cpm/pmol) and incubated at 30 °C for 20 min. The reaction was stopped by adding 30 µl of 2 × SDS sample buffer and boiling for 3 min. The reaction mixture was resolved by SDS-PAGE, and the phosphorylation of c-Jun was visualized by autoradiography.

Immune Complex Kinase Assay for JNK1 Activity

To assay for the activity of JNK1, MCF-7/ADR cells transfected with pcDNA3-JNK1FLAG were lysed in lysis buffer (100 mM sodium phosphate, pH 7.4, 150 mM NaCl, 1% Nonidet P-40, and 0.1% SDS). The lysates were incubated with 3 µg of M2 antibody (Eastman Kodak Co.) for 1 h followed by incubation with protein A-agarose beads (Life Technologies, Inc.). The immunoprecipitates were collected by centrifugation at 10,000 × g for 2 min and washed four times with the lysis buffer. The immune complex kinase assay was performed with purified GST-c-Jun (1-135) fusion protein (a generous gift from Dr. Kyriakis) as described (22). Briefly, a 20-µl aliquot of purified GST-c-Jun (1-135) (0.2 mg/ml in the kinase assay buffer) was added to the immunoprecipitate. The reaction was initiated by adding [gamma -32P]ATP to a final concentration of 100 µM (2500 mCi/mmol) and incubated at 30 °C for 20 min before being stopped by adding 30 µl of 2 × SDS sample buffer and boiling. The reaction mixture was resolved by SDS-PAGE, and the phosphorylation of c-Jun was visualized by autoradiography.

Tyrosine Kinase Assay

src family kinases, (Abl, Fyn, Lck, and Lyn kinase) were immunoprecipitated from MCF-7/ADR cells as described for JNK1, using the appropriate antibodies (Santa Cruz, Santa Cruz, CA). The assays were carried out using a tyrosine kinase assay kit (Upstate Biotechnology), which employs synthetic peptides as substrates. The reaction mixture (45 µl) contained the assay buffer (250 mM Tris, pH 7.0, 125 mM MgCl2, 25 mM MnCl2, and 0.25 mM Na3PO4), 0.5 mM [gamma -32P] ATP (2000 cpm/pmol), 1.5 mM substrate peptide stock, and the immunoprecipitated src family kinase resuspended in 20 µl of dilution buffer (200 mM Hepes, pH 7.0, 10% glycerol, and 0.1% Nonidet P-40). The reactions were incubated at 30 °C for 15 min and terminated by the addition of 10 µl of 50% acetic acid. The samples were centrifuged at 9000 rpm in a microcentrifuge for 2 min, and 25 µl of the supernatant from each tube was spotted onto a 2.1-cm p81 phosphocellulose filter paper disc (Whatman, Hillsboro, OR). The filter discs were washed three times with 0.75% phosphoric acid, washed once with acetone, and air dried. The amount of [32P]PO4 incorporated into the peptide substrate was determined by counting the filter discs in a Packard 2200 CA Tri-Carb scintillation counter.

Antisense Oligonucleotide Treatment

Antisense treatment was carried out as described (23) with modifications. MCF-7/ADR cells were grown in 60-mm Petri dishes until they were 60-70% confluent and washed twice with McCoy's 5A medium without serum. The antisense mixture was made by combining solution A (20 mg/ml Lipofectace in 0.25 ml of McCoy's 5A medium without serum) and solution B (400 nM of the antisense oligonucleotide in 0.25 ml of McCoy's 5A medium without serum). The antisense mixture was incubated at room temperature for 15 min, diluted to 2 ml with McCoy's 5A medium without serum, and applied to cells. The cells were incubated at 37 °C for 4 h and washed once with McCoy's 5A with 10% serum, and the incubation was continued for 48 h before harvesting.

Ras Activity Assay

MCF-7/ADR cells were grown in 60-mm Petri dishes, washed twice with phosphate-free McCoy's medium containing dialyzed serum, and incubated in the same medium for 45 min. The medium was replaced by phosphate-free McCoy's containing 0.25 mCi/ml [32P]orthophosphate (ICN, Irvine, CA), and the incubation was continued for an additional 3 h. After the glucose deprivation treatment, the cells were lysed in 500 ml of lysis buffer (50 mM Tris, pH 7.4, 20 mM MgCl2, 150 mM NaCl, 1% Nonidet P-40, 2 mM phenylmethylsulfonyl fluoride, 10 µg/ml leupeptin, 10 µg/ml aprotinin, 1 µg/ml pepstatin A, and 2 mM vanadate) containing 20 µg of monoclonclonal rat-anti-Ras antibody (Oncogene Science, Cambridge, MA). Nuclei were removed by centrifugation. The supernatant was incubated at 4 °C for 2 h on a rotating wheel. A 50-µl aliquot of protein G-agarose (Oncogene Science) linked to goat anti Rat IgG (Oncogene Science) was added, and the mixture was further incubated for 1 h. The immunoprecipitate was collected by centrifugation, washed four times in lysis buffer, and washed once with phosphate-buffered saline buffer. The pellet was resuspended in 15 ml of 0.75 M KH2PO4, pH 3.4, and boiled for 5 min. Separation of the Ras bound GTP and GTP was carried out on polyethyleneimine-cellulose TLC plates in 0.75 M KH2PO4, pH 3.4, followed by autoradiography of the TLC plates. The autoradiograph was subjected to densitometric analysis, and the extent of Ras activation was calculated by the ratio of the relative intensity of GTP/(GTP + GDP).


RESULTS

Hypoglycemia-induced Tyrosine Phosphorylation in MCF-7/ADR Cells

To investigate whether glucose deprivation can activate cellular protein tyrosine kinases, MCF-7/ADR cells were incubated in glucose-free medium and harvested at various time points. Western blot analysis with anti-phosphotyrosine antibody showed that there was a significant increase in tyrosine phosphorylation of cellular proteins (Fig. 1). Such increase of tyrosine phosphorylation was detectable within 5 min during glucose deprivation treatment to at least 2 h after the treatment. The early increase of tyrosine phosphorylation led us to hypothesize that activation of protein tyrosine kinases is probably one of the upstream signals of the glucose deprivation-induced response in MCF-7/ADR cells.


Fig. 1. Hypoglycemia-induced tyrosine phosphorylation. MCF-7/ADR cells were treated in glucose-free medium for different time intervals as indicated in the figure. An equal amount of protein (30 µg) from the cell lysates was separated by SDS-PAGE and analyzed by Western blotting with anti-phosphotyrosine antibodies.
[View Larger Version of this Image (0K GIF file)]

Activation of Lyn Kinase by Hypoglycemic Treatment of MCF-7/ADR Cells

Because src family kinases have been shown to be involved in a variety of cellular responses, such as to growth factors, oxidative stress, and G protein-coupled signaling cascades (24-26), we tested the possibility that src family tyrosine kinases are involved in the hypoglycemia-induced responses in MCF-7/ADR cells. Several src family members, Abl, Fyn, Lck, and Lyn kinases were immunoprecipitated from MCF-7/ADR cell lysates after glucose deprivation treatment. Tyrosine kinase assay of the immunoprecipitates showed that although the activities of Abl, Fyn, and Lck kinases were not significantly changed during the 4 h of the glucose deprivation treatment, Lyn kinase was activated 3~4-fold (Fig. 2). The activation of Lyn kinase was obvious within 5 min during the glucose deprivation treatment and lasted for at least 4 h. Compared with the time course of tyrosine phosphorylation in MCF-7/ADR cells under the same conditions, the early activation of Lyn kinase indicates that the activated Lyn kinase is involved in the induction of tyrosine phosphorylation in MCF-7/ADR cells during glucose deprivation treatment.


Fig. 2. Activation of Lyn kinase by hypoglycemic treatment of MCF-7/ADR cells. Lyn, Abl, Lck, and Fyn kinases were immunoprecipitated from cell lysates after incubation in glucose-free medium for different time intervals. The kinase activities in the immunoprecipitates were assayed using a synthetic peptide as substrate (see "Materials and Methods" for details). The symbols used in the figure are: bullet , Lyn; black-diamond , Lck; black-triangle, Abl; black-square, Fyn.
[View Larger Version of this Image (0K GIF file)]

Hypoglycemia-induced Phosphorylation of c-Jun by JNK1

To investigate the mechanism for the induction of AP-1 activity during glucose deprivation treatment, we assayed for c-Jun kinase activity in the lysates of MCF-7/ADR cells using recombinant GST-c-Jun as the substrate. Fig. 3A showed that there was a significant increase in c-Jun phosphorylation after glucose deprivation treatment. To further confirm that the observed activation of c-Jun kinase activity was due to an increase in JNK1 activity, we performed the kinase assay using transfected MCF-7/ADR cells that express an epitope (FLAG)-tagged JNK1. We observed that JNK1 immunoprecipitated from the transfected cells after hypoglycemic treatment caused significantly greater phosphorylation of GST-c-Jun than untreated cells, indicating that JNK1 is strongly activated by the glucose deprivation treatment (Fig. 3B). However, when the similar assays were performed using ERK1 and ERK2 immunoprecipitated from glucose deprivation-treated MCF-7/ADR cells, we did not detect any significant phosphorylation of c-Jun by ERKs (Fig. 3C).


Fig. 3. Hypoglycemia-induced phosphorylation of c-Jun by JNK1 but not by ERK1. Cells were treated in glucose-free medium and harvested at the time intervals indicated in the figure. Cell lysis and immune complex kinase assay were performed as described (see "Materials and Methods"). A, autoradiograph of the c-Jun kinase assay, showing the phosphorylation of GST-c-Jun by c-Jun-associated kinases. B, autoradiograph of the immune complex JNK1 assay, showing the phosphorylation of c-Jun by immunoprecipitated JNK1. C, autoradiograph of the assay for the phosphorylation of GST-c-Jun by immunoprecipitated ERK1.
[View Larger Version of this Image (0K GIF file)]

Lyn Antisense Oligonucleotide Inhibited Glucose Deprivation-induced Lyn Kinase and JNK1 Activity

To study whether the activation of Lyn kinase participated in signaling to the activation of c-Jun, we examined the effect of Lyn antisense oligonuleotide on glucose deprivation-induced c-Jun kinase activity in MCF-7/ADR cells. Fig. 4A showed that compared with treatment with Lyn sense oligonucleotide, Lyn antisense oligonuleotide inhibited over 80% of Lyn kinase activity in cells growing in normal medium and in the glucose-free medium. The JNK kinase assay demonstrated that antisense treatment markedly reduced glucose deprivation-induced JNK1 activity in MCF-7/ADR cells (Fig. 4B). On the other hand, we did not detect any inhibition of glucose deprivation-induced ERK activation with the antisense treatment (Fig. 4C). These results suggest that Lyn kinase is responsible for hypoglycemia-induced JNK1 activation but not ERK activation in MCF-7/ADR cells.


Fig. 4. The effect of Lyn antisense oligonucleotide on hypoglycemia-induced Lyn kinase, JNK1, and ERK activity. Cells were treated with the antisense oligonucleotide as described in the text and incubated in glucose-free medium for various time intervals as indicated in the figure. A, activity of Lyn kinase immunoprecipitated from lysates of Lyn antisense-treated cells (open circle ) or sense (bullet ) oligonucleotide-treated cells. B, immune complex assay for JNK1 activity from cells treated with Lyn sense or antisense oligonucleotide. C, Western blot with antibodies against ERK, showing the glucose deprivation-induced ERK activation in cells treated with Lyn sense or antisense oligonucleotide. The band for activated ERK is marked by <, and the band for the unphosphorylated ERK is marked by left-arrow .
[View Larger Version of this Image (0K GIF file)]

Hypoglycemia-induced Ras Activation in MCF-7/ADR Cells

Because it has been demonstrated that Ras can activate the JNK pathway, we examined the extent of Ras activation in MCF-7/ADR cells after hypoglycemia treatment. The activation state of p21ras was measured by metabolic labeling with [32P]orthophosphate and then lysing the cells followed by immunoprecipitation of Ras. TLC assay was performed to determine the amount of GTP and GDP bound to Ras. Fig. 5 showed that there was a significant increase in GTP bound Ras after 5 min of glucose deprivation treatment in MCF-7/ADR cells. Densitometric analysis of the autoradiograph showed that the percentage of active Ras increased approximately 4.5-fold during hypoglycemic treatment.


Fig. 5. Activation of p21c-ras by hypoglycemic treatment. Cells were incubated with phosphate-free medium and then labeled with [32P]H3PO4 for 3 h. The cells were treated with glucose-free medium for 5 min. p21c-ras was immunoprecipitated with rat monoclonal antibody Y13-259, and the bound guanine nucleotides were separated by thin-layer chromatography.
[View Larger Version of this Image (0K GIF file)]


DISCUSSION

The study reported here demonstrated a possible signal transduction pathway in MCF-7/ADR cells that responds to hypoglycemic conditions. Lyn kinase was initially activated by hypoglycemic conditions. Activation of Lyn kinase causes the activation of JNK1, which further phosphorylates and activates c-Jun. Being the major component of the AP-1 transcription factor, c-Jun, once activated, can subsequently activate the transcription of genes, such as bFGF, which contain AP-1 elements (20). The fact that the c-jun gene itself also contains an AP-1 element in its promoter indicates that phosphorylation of c-Jun allows signals in this pathway to be amplified. First, phosphorylation of c-Jun activates the transcription of c-jun per se, increasing the amount of available c-Jun for the formation of the AP-1 complex. Second, phosphorylation of c-Jun also increases the activity of the newly formed AP-1 factors, allowing the AP-1 transcriptional activity to be further activated.

Although JNK and ERK both belong to the mitogen-activated protein kinase superfamily and are structurally homologous, recent studies have demonstrated that their functions appear to be divergent. JNK, also referred to as stress-activated protein kinase, is a more potent c-Jun kinase than ERK. JNK is primarily induced by stress conditions such as UV radiation (21), hypoxia (27), and osmotic shocks (28). Consistently, we found that a different kind of stress, glucose deprivation, also stimulated JNK1, which is directly responsible for the activation of c-Jun and subsequently the induction of bFGF gene expression. However, data from this and a previous study (29) showed that ERK was also activated by hypoglycemic treatment of MCF-7/ADR cells. The duration of ERK activation was more than 1 h, more persistent than the activation of JNK1, suggesting that hypoglycemia-induced ERK activity probably have some specific function. ERK is responsible for the phosphorylation and activation of the TCF, which is involved in the transcriptional regulation of c-fos. Therefore, it is possible that ERK is responsible for the observed induction of c-fos gene expression induced by hypoglycemia (20). This speculation remains to be tested in future studies.

Lyn kinase, a membrane-associated src family kinase, has been shown to be involved in a variety of signaling responses, including to chemoattractant receptors (30), radiation (31), and B cell receptor activation (32). In this study, we demonstrated that Lyn kinase activity also can be stimulated by hypoglycemic treatments. Although the downstream substrates of Lyn kinase are largely unknown, recent studies indicate that activated Lyn kinase phosphorylates and associates with the adapter protein Shc through SH2 domain interactions (30). The activated Shc can further associate with the Grb2-Sos complex, leading to the activation of the Ras-dependent pathway (33, 34). Our data from the experiments with Lyn antisense oligonucleotide provided direct evidence that Lyn kinase is responsible for the activation of JNK1. In this study, we also observed the activation of Ras in glucose deprivation-treated MCF-7/ADR cells. It is likely that the activation of JNK1 by Lyn kinase is achieved in a Ras-dependent fashion, possibly through the activation of MEKK, the activator of JNK1, as demonstrated by other investigators (35, 36). Therefore, we propose that the signal transduction sequence of Lyn right-arrow Ras right-arrow MEKK right-arrow JNK1 right-arrow c-Jun is responsible for the hypoglycemia-induced c-Jun activation in MCF-7/ADR cells.

It remains to be understood how glucose deprivation treatment triggered the activation of Lyn kinase. Preliminary data in our laboratory demonstrated that the activation of Lyn kinase and JNK1 by glucose deprivation treatment of MCF-7/ADR cells can be inhibited by N-acetyl-cysteine, a free radical scavenger, suggesting that free radicals are involved in the glucose deprivation-induced response. Other reports have shown that src family kinases, including Lyn kinase, also can be activated by ionizing radiation and reactive oxygen (31, 37), which induce cellular free radicals. It is likely that Lyn kinase is activated by a common mechanism mediated by free radicals. Further studies are under way to test this possibility.


FOOTNOTES

*   This work was supported through National Institutes of Health Grants CA 48000 and CA 44550 and William Beaumont Hospital Grant 96-03.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Dagger    To whom correspondence should be addressed: Dept. of Radiation Oncology Research Laboratories, William Beaumont Hospital, 3601 W. Thirteen Mile Rd., Royal Oak, MI 48073. Tel.: 810-551-2568; Fax: 810-551-2443.
1   The abbreviations used are: bFGF, basic fibroblast growth factor; JNK, c-Jun N-terminal kinase; SRE, serum response element; TCF, ternary complex factor; ERK, extracellular signal-regulated kinase; GST, glutathione S-transferase; PAGE, polyacrylamide gel electrophoresis; MEKK, mitogen-activated response kinase kinase kinase.

REFERENCES

  1. Plate, K. H., Breier, G., Millauer, B., Ullrich, A., and Risau, W. (1993) Cancer Res. 53, 5822-5827 [Abstract]
  2. Millauer, B., Shawver, L. K., Plate, K. H., Risau, W., and Ullirich, A. (1994) Nature 367, 576-579 [CrossRef][Medline] [Order article via Infotrieve]
  3. Witte, L., Fuks, Z., Haimovitz-Friedman, A., Vlodavsky, I., Goodman, D. W., and Eldor, A (1989) Cancer Res. 49, 5066-5072 [Abstract]
  4. Haimovitz-Friedman, A., Vlodavsky, I., Chaudhuri, A., Witte, L., and Fuks, Z. (1991) Cancer Res. 51, 2552-2558 [Abstract]
  5. Winkles, J. A., Peifley, K. A., and Friesel, R. E. (1992) Cancer Res. 52, 1040-1043 [Abstract]
  6. Kim, S. J., Glick, A., Sporn, M. B., and Roberts, A. B. (1989) J. Biol. Chem. 264, 402-408 [Abstract/Free Full Text]
  7. Kim, S. J., Denhez, F., Kim, K. Y., Holt, J. T., Sporn, M. B., and Roberts, A. B. (1989) J. Biol. Chem. 264, 19373-19378 [Abstract/Free Full Text]
  8. Shibata, F., Baird, A., and Florkiewicz, R. Z. (1991) Growth Factors 4, 2177-2187
  9. Angel, P., Hattori, K., Smeal, T., and Karin, M. (1988) Cell 55, 875-885 [Medline] [Order article via Infotrieve]
  10. Deng, T., and Karin, M. (1993) Genes & Dev. 7, 479-490 [Abstract]
  11. Pulverer, B. J., Kyriakis, J. M., Avruch, J., Nikolakaki, E., and Woodgett, J. R. (1991) Nature 353, 670-674 [CrossRef][Medline] [Order article via Infotrieve]
  12. Smeal, T., Binetruy, B., Mercola, D. A., Birrer, M., and Karin, M. (1991) Nature 354, 494-496 [CrossRef][Medline] [Order article via Infotrieve]
  13. Smeal, T., Binetruy, B, Mercola, D., Grover, B. A., Heidecker, G., Rapp, U. R., and Karin, M. (1992) Mol. Cell. Biol. 12, 3507-3513 [Abstract]
  14. Abel-Hafiz, H. A. M., Heasley, L. E., Kyriakis, J. M., Avruch, J., Kroll, D. J., Johnson, G. L., and Hoeffler, J. P. (1992) Mol. Endocrinol. 6, 2079-2089 [Abstract]
  15. Gupta, S., Campbell, D., Derijard, B., and Davis, R. J. (1995) Science 267, 389-393 [Medline] [Order article via Infotrieve]
  16. Treisman, R. (1986) Cell 46, 567-574 [Medline] [Order article via Infotrieve]
  17. Treisman, R. (1992) Trends Biochem. Sci. 17, 423-426 [CrossRef][Medline] [Order article via Infotrieve]
  18. Gille, H., Sharrocks, A. D., and Shaw, P. E. (1992) Nature 358, 414-417 [CrossRef][Medline] [Order article via Infotrieve]
  19. Marais, R., Wynne, J., and Treisman, R. (1993) Cell 73, 381-393 [Medline] [Order article via Infotrieve]
  20. Galoforo, S. S., Berns, C. M., Erdos, G., Corry, P. M., and Lee, Y. J. (1996) Mol. Cell. Biochem. 155, 163-171 [Medline] [Order article via Infotrieve]
  21. Derijard, B., Hibi, M., Wu, I., Barrett, Y., Su, B., Deng, T., Karin, M., and Davis, R. J. (1994) Cell 76, 1025-1037 [Medline] [Order article via Infotrieve]
  22. Kyriakis, J. M., Banerjee, P., Nikolakaki, E., Dai, T., Rubie, E. A., Avruch, J., and Woodgett, J. (1994) Nature 369, 156-160 [CrossRef][Medline] [Order article via Infotrieve]
  23. Dean, N. M., and McKay, R. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 11762-11766 [Abstract/Free Full Text]
  24. Gould, K., and Hunter, T. (1988) Mol. Cell. Biol. 8, 3345-3356 [Medline] [Order article via Infotrieve]
  25. Mukhopadhyay, D., Tsiokas, L., Zhou, X., Foster, D., Brugge, J. S., and Suhatme, V. P. (1995) Nature 375, 577-581 [CrossRef][Medline] [Order article via Infotrieve]
  26. Wan, Y., Kurosaki, T., and Huang, X. Y. (1996) Nature 380, 541-544 [CrossRef][Medline] [Order article via Infotrieve]
  27. Pombo, C. M., Bonvente, J. V., Avruch, J., Woodgett, J. R., Kyriakis, J. M., and Force, T. (1994) J. Biol. Chem. 269, 26546-26551 [Abstract/Free Full Text]
  28. Galcheva-Gargova, Z., Derijard, B., Wu, I.-H., and Dadis, R. J. (1994) Science 265, 806-808 [Medline] [Order article via Infotrieve]
  29. Gupta, A. K., Lee, Y. J., Galoforo, S. S., Berns, C. M., Martinez, A. A., Corry, P. M., Wu, X.-Y., and Guan, K.-L. (1996) Mol. Cell. Biochem., in press
  30. Ptasznik, A., Traynor-Kaplan, A., and Bolcoch, G. M. (1995) J. Biol. Chem. 270, 19969-19973 [Abstract/Free Full Text]
  31. Yang, C., Maruyama, S., Yanagi, S., Wang, X., Takata, M., Kurosaki, T., and Yamamura, H. (1995) J. Biochem. (Tokyo) 118, 33-38 [Abstract]
  32. Myers, D. E., Jun, C., Waddick, K. G., Forsyth, L., Chelstrom, L. M., Gunther, R. L., Tumer, N. E., Bolen, J., and Uckun, F. M. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 9575-9579 [Abstract]
  33. Li, N., Batzer, A., Daly, R., Yajnik, V., Skolnik, E., Chardin, P., Bar-Sagu, D., Margolis, B., and Schlessinger, J. (1993) Nature 363, 85-88 [CrossRef][Medline] [Order article via Infotrieve]
  34. Chardin, P., Camonis, J. H., Gale, N. W., Van Aelst, L., Schlessinger, J., Wigler, M. H., and Bar-Sagi, D. (1993) Science 260, 1338-1343 [Medline] [Order article via Infotrieve]
  35. Sanchez, I., Hughes, R. T., Mayer, B. J., Yee, K., Woodgett, J. R., Avruch, J., Kyriakis, J. M., and Zon, L. I. (1994) Nature 372, 794-798 [Medline] [Order article via Infotrieve]
  36. Yan, M., Dai, T., Deak, J. C., Kyriakis, J. M., Zon, L. I., Woodgett, J. R., and Templeton, D. J. (1994) Nature 372, 798-800 [Medline] [Order article via Infotrieve]
  37. Schieven, G. L., Kirihara, J. M., Myers, D. E., Ledbetter, J. A., and Uckun, F. M. (1993) Blood 82, 1212-1220 [Abstract]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.